Introduction: Sucralose is a non-nutritive sweetener that has shown to decrease insulin sensitivity through mechanisms including changes in intestinal microbiota.
Objective: To determine the impact of sucralose on insulin sensitivity and gut microbiota in healthy individuals.
Methods: Parallel triple-blind randomized clinical trial including 24 healthy individuals, not habitual users of nonnutritive sweeteners. Individuals were instructed to maintain dietary and physical activity habits and randomized to consume capsules with 30% of the acceptable daily intake of sucralose or placebo for 30 days. Hyperinsulinemic euglycemic clamp was performed before and after the intervention, M/I value change was calculated and compared. Stool samples were taken at baseline and the final visit, DNA extraction was carried out with a QIAamp DNA stool Mini Kit.
Results: The M/I value adjusted for free fat mass decreased in the sucralose group vs placebo (p<0.01). Reduction in the alpha diversity of gut microbiota (p<0.0002) was observed in sucralose consuming group vs placebo (p=0.2369) and an increase in the Gram (-) bacteria Bacteroides fragilis associated to a significant increase in serum LPS were documented.
Conclusion: Sucralose consumption causes a significant decrease in insulin sensitivity associated to changes in gut microbiota composition and endotoxemia in healthy individuals.
A. Romo-Romo: None. M. Sanchez-Tapia: None. N. Torres: None. C.A. Aguilar-Salinas: None. A.J. Martagon: None. M. López-Carrasco: None. L.E. Guillén-Pineda: None. P. Gomez-Aviles: None. G.X. Brito: None. F.J. Gómez-Perez: None. P. Almeda-Valdes: None.
CONAHCYT Ciencia de Frontera 2019/316514
